These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 6540987)

  • 1. Increased releasable vascular plasminogen activator and a bleeding diathesis.
    Walther PJ; Gore M; Pizzo SV
    Am J Med; 1984 Sep; 77(3):566-8. PubMed ID: 6540987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenteric vein thrombosis and vascular plasminogen activator.
    Boyko OB; Pizzo SV
    Arch Pathol Lab Med; 1983 Oct; 107(10):541-2. PubMed ID: 6688517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
    Schleef RR; Higgins DL; Pillemer E; Levitt LJ
    J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory evaluation of patients with undiagnosed bleeding disorders.
    Alves GS; Orsi FA; Santiago-Bassora FD; Quaino SK; Montalvão SA; Paula EV; Annichino-Bizzacchi JM
    Blood Coagul Fibrinolysis; 2016 Jul; 27(5):500-5. PubMed ID: 26825625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Children with hemorrhagic diathesis: correct diagnostic and therapeutic approach].
    Carnelli V; Dozzi M; Gibelli M; Giovanniello A; Riva F; Seidita C; Stucchi C
    Pediatr Med Chir; 1990; 12(1):1-13. PubMed ID: 2198546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha 2-Antiplasmin Enschede: dysfunctional alpha 2-antiplasmin molecule associated with an autosomal recessive hemorrhagic disorder.
    Kluft C; Nieuwenhuis HK; Rijken DC; Groeneveld E; Wijngaards G; van Berkel W; Dooijewaard G; Sixma JJ
    J Clin Invest; 1987 Nov; 80(5):1391-400. PubMed ID: 2445779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
    Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
    J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation.
    Lijnen HR; Soria J; Soria C; Collen D; Caen JP
    Thromb Haemost; 1984 Feb; 51(1):108-9. PubMed ID: 6539000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
    Agren A; Wiman B; Schulman S
    Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite.
    Husain SS; Lipinski B; Greuwich V
    Proc Natl Acad Sci U S A; 1981 Jul; 78(7):4265-9. PubMed ID: 6270665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Releasing the Brakes on the Fibrinolytic System in Pulmonary Emboli: Unique Effects of Plasminogen Activation and α2-Antiplasmin Inactivation.
    Singh S; Houng A; Reed GL
    Circulation; 2017 Mar; 135(11):1011-1020. PubMed ID: 28028005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Releasing of plasminogen-activator from the kidney to the blood (author's transl)].
    Nakata A; Hagita M; Okamoto U
    Nihon Seirigaku Zasshi; 1978 Nov; 40(11):419-26. PubMed ID: 155161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration.
    Collen D; Stassen JM; Verstraete M
    J Clin Invest; 1983 Feb; 71(2):368-76. PubMed ID: 6681615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interaction of streptokinase.plasminogen activator complex, tissue-type plasminogen activator, urokinase and their acylated derivatives with fibrin and cyanogen bromide digest of fibrinogen. Relationship to fibrinolytic potency in vitro.
    Cassels R; Fears R; Smith RA
    Biochem J; 1987 Oct; 247(2):395-400. PubMed ID: 3122725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inherited fibrinolytic disorder due to an enhanced plasminogen activator level.
    Aznar J; Estellés A; Vila V; Regañón E; España F; Villa P
    Thromb Haemost; 1984 Oct; 52(2):196-200. PubMed ID: 6543037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periorbital ecchymoses as the initial sign in multiple myeloma.
    Loo H; Forman WB; Levine MR; Crum ED; Rassiga AL
    Ann Ophthalmol; 1982 Nov; 14(11):1066-8. PubMed ID: 7181338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrinsic plasminogen activator: a new principle in fibrinolysis.
    Lijnen HR
    Behring Inst Mitt; 1983 Aug; (73):43-55. PubMed ID: 6236789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha2-plasmin-inhibitor deficiency (Miyasato disease).
    Koie K; Kamiya T; Ogata K; Takamatsu J
    Lancet; 1978 Dec 23-30; 2(8104-5):1334-6. PubMed ID: 82839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tissue plasminogen activator: mechanism of action and thrombolytic properties].
    Páramo JA; Collen D
    Sangre (Barc); 1984; 29(4-C):767-73. PubMed ID: 6393389
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.